Cullinan Therapeutics Presents Positive Updated Data from Module C of Zipalertinib Pivotal Phase 2b Study at ESMO 2024
September 14, 2024 04:15 ET
|
Cullinan Therapeutics, Inc.
Updated data show consistent objective response rate of 40% and manageable safety profile in patients with non-small cell lung cancer harboring epidermal growth factor receptor exon 20 insertion...
Black Diamond Therapeutics Presents Real-World Treatment Practices and Patient Outcomes in Newly Diagnosed NSCLC Patients with Non-Classical Mutations at the European Society for Medical Oncology (ESMO) Congress 2024
September 14, 2024 03:30 ET
|
Black Diamond Therapeutics, Inc
Treatment data were analyzed from 3,276 cases of patients with newly diagnosed EGFR mutant NSCLC from Guardant Health Analyses of patients with non-classical EGFR mutations reveal that the majority...
RYBREVANT®▼ (amivantamab) plus chemotherapy shows positive overall survival trend versus chemotherapy in patients with previously treated EGFR-mutated lung cancer
September 14, 2024 03:15 ET
|
Janssen Cilag International NV
Post-progression outcomes showed significant and sustained improvement for amivantamab plus chemotherapy versus chemotherapy alone1 BEERSE, BELGIUM , Sept. 14, 2024 (GLOBE NEWSWIRE) --...
Acrivon Therapeutics Reports Positive Endometrial Cancer Data from Ongoing ACR-368 Registrational Intent Phase 2 Study at ESMO, Advancement of ACR-2316 into Clinic Ahead of Timelines, and Progress on its AP3 Interactome for Proprietary Data Analysis
September 14, 2024 03:10 ET
|
Acrivon Therapeutics, Inc
Confirmed overall response rate (ORR) = 62.5% (95% CI, 30.4-86.5) observed in prospectively-selected ACR-368 OncoSignature-positive (BM+) patients with endometrial cancer Achieved statistically...
Transgene and BioInvent’s Oncolytic Virus BT-001 Shows Promising Antitumor Activity in Ongoing Phase I/IIa Trial in Solid Tumors that Failed Previous Treatments
September 14, 2024 03:05 ET
|
Transgene S.A.
Preliminary data presented at ESMO 2024 demonstrate that BT-001 induces tumor regression in patients who failed previous anti-PD(L)-1 treatment In a patient with a heavily pretreated...
NuCana Presents Encouraging Data on NUC-7738 in Combination with Pembrolizumab in PD-1 Inhibitor Refractory and Resistant Melanoma Patients at the ESMO Congress 2024
September 14, 2024 03:01 ET
|
NuCana plc
BARCELONA, Spain, Sept. 14, 2024 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) presented final data from the Phase 2 NuTide:701 study at the ESMO Congress on NUC-7738 in combination with...
Avacta Reports Updated Phase 1 Clinical Data of AVA6000 at the European Society for Medical Oncology (ESMO) Congress Demonstrating Multiple Ongoing, Durable Responses in Solid Tumors
September 14, 2024 03:00 ET
|
Avacta Group
This announcement contains inside information for the purposes of Article 7 of the UK version of Regulation (EU) No 596/2014 which is part of UK law by virtue of the European Union (Withdrawal) Act...
Immunocore presents Phase 1 data of brenetafusp, an ImmTAC bispecific targeting PRAME, in patients with ovarian cancer
September 14, 2024 03:00 ET
|
Immunocore Holdings plc
Immunocore presents Phase 1 data of brenetafusp, an ImmTAC bispecific targeting PRAME, in patients with ovarian cancer Brenetafusp is clinically active as monotherapy and in combination with...
B2B Payments Market Size is Surpassing USD 4,151.35 Billion by 2033, Growing at Projected 9.38% CAGR
September 14, 2024 03:00 ET
|
The Brainy Insights
Newark, Sept. 14, 2024 (GLOBE NEWSWIRE) -- The global B2B payments market, valued at USD 1,693.60 billion in 2023, is expected to grow at a CAGR of 9.38% from 2024 to 2033. This growth is driven by...
Sutro Biopharma Announces Updated Data from Phase 1b Study of Luvelta in Combination with Bevacizumab at ESMO 2024
September 14, 2024 03:00 ET
|
Sutro Biopharma, Inc.
- 4.3 mg/kg of luveltamab tazevibulin (luvelta) in combination with standard dose of bevacizumab (15 mg/kg) every 3 weeks resulted in a 56% objective response rate in patients with late-stage ovarian...
- September 13, 2024 19:21 ET Edward Jones expands presence in Atlantic Canada with first woman-led branch in Fredericton, New Brunswick
- September 13, 2024 17:41 ET LemVega Capital, the Leading Investment Management Firm, on Track to Become a Global Financial Powerhouse